FDA Warning Asks Novartis for Global Manufacturing Assessment

Washington Drug Letter
A A
The FDA is asking Novartis for a comprehensive, global manufacturing assessment after it sharply scored the company for multiple repeated quality failures at plants operated by its Sandoz subsidiary.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00